Table 2. Studies comparing the benefits of CGRP mAbs vs. botox.

CGRP: calcitonin gene-related peptide; mAbs: monoclonal antibodies; botox: OnabotulinumtoxinA.

Author and year of pub	Drug studied	Type of the study	Results
Do et al., 2019 [21]	CGRP mAb	Review	One thousand six hundred seventy-two patients were split randomly into groups of different dosages of galcanezumab and a placebo. 60.9% of the patients on 240 mg showed a >50% decrease in migraines. CGRP mAb was proven to decrease migraines and not have any detrimental side effects.
Akhtar et al, 2019 [11]	CGRP mAb	Review	Monoclonal antibodies against CGRP are much safer than their predecessors. There aren't any major short-term side effects.
Deen et al., 2017 [22]	CGRP mAb	Review	Monoclonal abs against CGRPs are more efficacious and have fewer side effects than older migraine-prophylaxis. They also don't have drug-drug interactions and do not have any significant hepatotoxic side effects. It is also given only once a month instead of daily, increasing compliance.
Yalinay et all, 2018 [23]	Botox	Observational	Two hundred forty-five patients enrolled in the study, and 180 answered questions about their treatment experience. 82.9% of patients felt that botox helped control their headaches. On a scale of 0-10, a mean score of 6.94 ± 2.4 was given for the effectiveness.
Dodick et al., 2010 [24]	Botox	Randomized control trial	A total of 1384 patients were given either a placebo or botox. Those on botox reported a more considerable decrease in migraines than those on the placebo
Chan et al., 2009 [25]	Botox	Observational	Twelve adolescents from ages 14-18 were given botox injections. All six long-term patients stated they experienced a better quality of life and had decreased migraines.